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Abstract—Motivation: The biological processes involved in a
drug’s mechanisms of action are oftentimes dynamic, complex
and difficult to discern. Time-course gene expression data is a
rich source of information that can be used to unravel these
complex processes, identify biomarkers of drug sensitivity and
predict the response to a drug. However, the majority of previous
work has not fully utilized this temporal dimension. In these
studies, the gene expression data is either considered at one
time-point (before the administration of the drug) or two time-
points (before and after the administration of the drug). This is
clearly inadequate in modeling dynamic gene-drug interactions,
especially for applications such as long-term drug therapy.
Results: In this work, we present a novel REcursive Prediction
(REP) framework for drug response prediction by taking advan-
tage of time-course gene expression data. Our goal is to predict
drug response values at every stage of a long-term treatment,
given the expression levels of genes collected in the previous
time-points. To this end, REP employs a built-in recursive
structure that exploits the intrinsic time-course nature of the
data and integrates past values of drug responses for subsequent
predictions. It also incorporates tensor completion that can not
only alleviate the impact of noise and missing data, but also
predict unseen gene expression levels (GELs). These advantages
enable REP to estimate drug response at any stage of a given
treatment from some GELs measured in the beginning of the
treatment. Extensive experiments on a dataset corresponding to
53 multiple sclerosis patients treated with interferon are included
to showcase the effectiveness of REP.
I. INTRODUCTION
Prediction of drug response based on patients’ clinical
and molecular features is a major challenge in personalized
medicine. Great effort has been devoted to identify molecular
biomarkers of drug sensitivity and to develop computational
models to predict drug response based on these biomarkers.
Gene expression data is one of the most commonly used
data type in these studies, due to their high predictive ability,
and numerous methods have been proposed for drug response
prediction based on gene expression data [1]–[7]. However,
many existing methods only use basal gene expression data
(i.e., gene expression values before administration of the drug)
and hence can only capture the influence of the steady state of
the cells on their response to a drug. For example, the authors
of [1] analyzed 44 drug response prediction methods that
employed gene expression profiles of breast cancer cell lines
taken before treatment to predict dose-response values, e.g.,
GI50–the concentration that inhibited cell growth by 50% after
72 hours of treatment. Similar work can also be found in [2]–
[4], which only incorporate gene expression data from a single
time-point. A collection of temporal gene expression profiles
of samples over a series of time-points during the course of a
biological process can provide more insights than a single (or
two) time-point(s) [8]. Therefore, developing algorithms that
can predict the drug response over time using time-course gene
data is of great interest.
With the advancement of gene sequencing technologies,
collecting gene expression data over multiple time-points and
their matched drug response values is now feasible. In parallel
with these technological developments, there has been growing
interest in the application of machine learning methods to
analyze the time-course gene expression data. In [9], the
authors proposed an integrated Bayesian inference system to
select genes for drug response classification from time-course
gene expression data. However, the method only uses the
data from the first time-point, and hence does not benefit
from the additional temporal information. Lin et al., [10]
presented a Hidden Markov model (HMM)- based classifier,
in which the HMM had fewer states than time points to align
different patient response rates. This discriminative HMM
classifier enabled distinguishing between good/bad responders.
Nevertheless, choosing the number of states for this HMM is
a major practical issue. In addition, this method cannot handle
missing data and it requires the full knowledge of GELs in all
time-points a priori. This implies that the HMM may not be
able to predict drug response at multiple stages in future time
points, since the corresponding GELs are not measurable.
The time-course gene expression data contains the GELs
of different patients over a series of time points, which can
be indexed as patient-gene-time and represented as a three-
dimensional tensor. Motivated by this, several tensor decom-
position based algorithms have been proposed. For example,
Taguchi [11] employed tensor decomposition to identify drug
target genes using time-course gene expression profiles of
human cell lines. Li and Ngom [12] proposed a higher-order
nonnegative matrix factorization (HONMF) tool for classifying
good or bad responders from a latent subspace corresponding
to patients learned from HONMF. One limitation of this work
is that the latent subspace may not have discriminative ability
in classifying patients, since it is learned without accounting
for the class-label information. Moreover, this method simply
discards samples with missing values, causing unnecessary
information loss.
Recently, Fukushima et al., [7] developed an algorithm for
joint gene selection and drug response prediction for time-
course data. The method uses Elastic-Net (EN) to select a set
of genes that show discrimination of patients’ drug responses
throughout the treatment. The selected genes are then passed
to a logistic regression (LR) classifier for drug response
prediction. But in real applications, due to the existence of
noise and missing values in the data, finding discriminative
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2genes for all patients may be difficult. In fact, several studies
have shown that it is more viable to find genes that have
consistent discrimination in a subset of samples along the time
series [13]–[15]. Therefore, relying only on discriminative
gene selection but without modifying classification algorithms
may not achieve satisfactory performance.
In this paper, we take a different approach for time-course
drug response prediction. We hypothesize that a patient’s
drug response at a given time-point can be inferred from the
response at a previous time point. This means that not only
the GELs but also the past response results can be integrated
to identify the drug response for a subsequent time point. We
develop a REcursive Prediction (REP) algorithm to predict
the drug response of samples using their time-course gene
expression data and their drug response at previous time-
points. REP has a built-in recursive structure that exploits the
intrinsic time-course nature of the data through integrating past
drug responses for subsequent prediction. In other words, in
REP, not only the GELs but also the past drug responses are
treated as features for drug response prediction. Furthermore,
by taking into consideration the intrinsic tensor structure of the
time-course gene expression data and leveraging identifiability
of low-rank tensors, REP can alleviate the noise corruption in
GEL measurements, complete missing GELs and even predict
GELs for subsequent time points. These features enable REP
to evaluate drug response at any stage of a given treatment
from some GELs measured in the beginning of a treatment.
Experiments on real data are included to demonstrate the
effectiveness of the REP algorithm.
II. METHOD
Fig. 1 sketches the idea behind the proposed REP algorithm,
where the subfigures 1(a)–1(c) show the pre-processing, model
training and prediction of our method, respectively. The tensor
structure of time-course gene expression data is shown in Fig.
1(a). In the following, we explain them in more detail.
A. Pre-processing
One major issue in using gene expression data for drug
response prediction is the existence of missing values. To
overcome this problem, we first impute the missing values
during pre-processing. Various methods have bene previously
suggested for handling missing values, such as median-
imputation [16] and nearest neighbor imputation [17], [18].
We employ a low-rank tensor model to fit the time-course
gene expression dataset such that the missing values can be
completed. Our supporting hypothesis is that genes never
function in an isolated way, but oftentimes groups of genes
interact together to maintain the complex biological process,
which results in correlation in the GEL data [19]. We note that
our low-rank tensor model suggests three factors that uniquely
determine the values of GELs, i.e., the factors corresponding
to patient, gene and time, respectively (see Fig. 1). As we
will see later, our model allows us to estimate the variation of
GEL over time from a set of initial GEL measurements; these
estimated values are then used to predict the time-course of
drug response.
Towards this goal, we first assume1 that each GEL is
represented as a summation of F triple products from the
latent factors of patient, gene and time, respectively. Let us
denote gijk as the jth GEL of patient i recorded at time k.
Based on our assumption, we have
gijk =
F∑
f=1
aifbjfckf (1)
where aif , bjf and ckf are the latent factors of patient,
gene and time, respectively. Suppose that there are J genes
measured over K time points. By varying the indices j and
k in (1), the expression of the genes in all the time-points in
patient i can be represented as
Gi = BDi(A)CT ∈ RJ×K (2)
where A ∈ RI×F , B ∈ RJ×F , C ∈ RK×F . In this equation,
Di(A) represents a diagonal matrix holding the ith row of
A as the main diagonal, which is a latent representation of
the ith patient. We use aif to represent the (i; f)-entry of A,
bjf to represent the (j; f)-entry of B and ckf to represent the
(k; f)-entry of C.
Assume that there are I patients in the training set. After
collecting {G1, · · · ,GI}, we stack them in parallel along the
patient-axis, which results in a GEL tensor that takes the form
of
G := JA,B,CK = F∑
f=1
af ◦ bf ◦ cf ∈ RI×J×K (3)
where ◦ is the outer product and af is the f th column of A,
and likewise for bf and cf . Here, we assume that G is the
noiseless GEL data and X is the corresponding noisy data
with missing values. The relationship between G and X is
described as
PΩ(X) = PΩ(G) + PΩ(N) (4)
where N is the noise in the data, Ω is the index set of the
observed GELs in X, and PΩ is the operator that keeps the
entries in Ω and zeros out the others.
The model in (2) indicates that the gene and time factors
(i.e., B and C) are identical for different patients, and the
variability among patients is captured by A. In other words,
given B and C, each row of the patient factor matrix A
uniquely determines the GELs of the corresponding patient.
As we will see later, our model is able to predict unseen GELs,
which also enables to prescreen the drug response for different
stages of a treatment.
Assuming nonnegative GELs2, we can use nonnegative
tensor factorization to compute missing GEL values:
min
A,B,C,G
‖G− JA,B,CK‖2F + λ (‖A‖2F + ‖B‖2F + ‖C‖2F )
s. t. PΩ(G) = PΩ(X),A ≥ 0,B ≥ 0,C ≥ 0 (5)
1For high-enough but finite F , any patient-gene-time dataset can be
expressed this way. See [20] for a tutorial overview of tensor rank decompo-
sition.
2Due to some preprocessing steps such as z-score normalization, the GEL
values can be negative. To facilitate our method, we undo these preprocessing
steps or use the raw dataset.
3(a) Pre-processing
(b) Training (c) Prediction
Fig. 1. Sketch view of the proposed method. In (a), Step 1) shows the raw data X with missing values marked as ‘black’; Step 2) shows the low-rank tensor
factorization; Step 3) is the missing completion, where Z = PΩ(X)+PΩc (G). In (b), it shows the composition of training data: features and labels. In (c),
it shows the prediction for new patient at a specific time t.
where many sophisticated algorithms are applicable to opti-
mize (5), e.g., block coordinate descent [20], [21]. Intuitively,
(5) seeks to identify the lowest rank solution G that best
matches the observations X. The regularization terms are
added to further encourage low rank and prevent over-fitting.
When (5) is solved, we complete the GEL data through
Z = PΩ(X) + PΩc(G) (6)
where Ωc contains the indices of missing values in X.
B. Training
The effects of drugs are usually cumulative over time [22],
i.e., drug doses taken in the past will affect the current
response. This implies that the drug response in the past
time-points may help predict the current response. Based on
this hypothesis, we propose a recursive prediction algorithm,
henceforth referred to as REP for simplicity, which enables
to integrate past drug response records with gene expression
values for subsequent drug response predictions. Fig. 1(c)
shows an overview of REP’s pipeline, where drug responses
{y0, · · · , y(t − 1)} in the previous time stages are integrated
with the gene expression information zt for predicting the
current response y(t). Here, we accumulate the historical
response as
y˜(t) =
t−1∑
i=0
y(i) (7)
which is then fed back as an input feature for subsequent
drug response prediction. The intuition behind (7) is that if
the responses at adjacent time stages are consistent, then the
response at the next stage is more likely to continue the
same pattern instead of going in the opposite direction. If the
responses at two adjacent time stages are opposite, i.e., one is
good and the other one is poor, their effect will be canceled
out in (7). In this case, the predictor will focus more on the
GELs.
Mathematically, we have
yi,t = f(zi,t, y˜i,t) (8)
where y˜i,t denotes the accumulated historical responses of
patient i at time t, f(·) is the predictor which can be trained
by minimizing the following cost function
L(θ) =
1
IK
I∑
i=1
K∑
t=1
`(f(zi,t, y˜i,t), yi,t) + λr(θ) (9)
where θ contains the parameters of the predictor, `(·) is the
loss function of a classifier such as hinge loss and cross-
entropy loss, r(·) is a regularizer that imposes a certain
structure on θ, and λ ≥ 0 is a regularization parameter.
In the literature, popular regularizers include r(θ) = ‖θ‖22,
r(θ) = ‖θ‖0, r(θ) = ‖θ‖1 and r(θ) = 1+(θ), i.e., the
indicator function of the nonnegative orthant.
For the purpose of illustration, we are particularly interested
in but not limited to the SVM classifier. We set θ = [uT , v]T
and `(·) as hinge loss, resulting in
min
u,v,b
{
1
IK
I∑
i=1
K∑
t=1
max
(
0, 1− yi,t(uT zi,t + ρvy˜i,t + b)
)
+
λ
2
(‖u‖22 + |v|2)}
s. t. [uT , v]T ∈ C (10)
where b is the intercept, C denotes a convex set such as `1-
ball for feature selection and ρ represents the importance of the
response at a previous time point on the subsequent one. In our
formulation, the drug response feedback plays an important
role and it can be viewed as a “must-have” feature. Therefore,
4the hyper-parameter ρ is critical for the performance of REP.
In practice, we recommend to choose a relatively large ρ in
an incremental fashion.
Remark 1: The major difference between (10) and the stan-
dard SVM-based drug response predictors lies in the feedback
y˜i,t: prior art ignored the previous drug response outputs. For
the initial time point, there is no response feedback, i.e., yi,0
does not exist. So how do we choose yi,0? One way could be
yi,0 = 0 which can be interpreted as uncertainty, i.e., we do
not know how the patient responds to a treatment. Then we
construct the following feedback matrix:
Y˜ =

y˜1,1 y˜1,2 · · · y˜1,K
y˜2,1 y˜2,2 · · · y˜2,K
...
y˜I,1 y˜I,2 · · · y˜I,K
 (11)
where y˜i,1 = 0,∀i = 1, · · · , I . Finally, the features in the
training set is formed by concatenating Y˜ in Z along the gene-
axis as shown in the left-bottom corner of Fig. 1(b), and the
training labels are
Y =

y1,1 y1,2 · · · y1,K
y2,1 y2,2 · · · y2,K
...
yI,1 yI,2 · · · yI,K
 . (12)
C. Drug response prediction
Our method can predict the drug response values for a new
patient at any time point. Specifically, given the GELs of a new
patient at time t, i.e., x(t), we first check if there are missing
values. If so, we employ the factors B and C to complete x(t).
Let us denote Ω¯ and Ω¯c as the sets of indices of the observed
and missing elements in x(t). According to our model in (1),
x(t) can be uniquely determined by B, C and an unknown
vector a–a latent representation of this new patient. Thus, for
the expression level of the jth gene at time t, we have
xj(t) =
[
bj1 · · · bjF
] a1 . . .
aF

ct1...
ctF
+ n
= (C(t, :)B(j, :))a+ nj , ∀j ∈ Ω¯ (13)
where nj is the additive noise which is assumed as Gaussian
distributed,  is the Khatri-Rao (column-wise Kronecker)
product, and B(j, :) and C(t, :) denote the tth row of B and
C, respectively.
Since B and C are known, the problem of estimating a can
be formulated as
aˆ = arg min
a≥0
∑
j∈Ω¯
(
xj(t)− (C(t, :)B(j, :))a
)2
(14)
which is a nonnegative least squares (NLS) problem and can be
optimally solved. We note that to obtain a unique estimate aˆ,
the number of available gene expression entries in x(t) should
be ≥ F . The GEL vector of the patient is then estimated as
g(t) = (C(t, :)B) aˆ (15)
which leads to a completed GEL vector
z(t) = PΩ¯(x(t)) + PΩ¯c(g(t)). (16)
The vector z(t) together with the cumulated historical drug
response y˜(t), are the input data for our predictor f(·). We
estimate the drug response of this patient at time t via
yˆ(t) = f (z(t), y˜(t)) . (17)
1) Predicting Unseen GELs: Previously, we have explained
how to predict drug response for patients at a certain time
point. However, in practice, we are more interested in knowing
the drug response of a few time-points in the future from the
beginning of a treatment. This requires to know the GELs of
all time points up to the time-point of interest a priori, which
is impossible in practice. In this subsection, we provide an
efficient solution that allows to predict the unseen GELs.
Recall that in our model, the GEL of a patient is determined
by three factors, i.e., the latent representation of patient–a, the
time evolution factor–B and the gene factor matrix–C, where
a is different for patients, and needs to be estimated for the
new patient. On the other hand, B and C are common gene
and time evolution bases that reflect different types of patients,
as determined from historical patient data – the training data.
Therefore, the problem boils down to the estimation of a from
the initial GELs of the new patient. We can simply substitute
t = 1 in (14) to find aˆ. Finally, the GELs for the remaining
time points are estimated as
xˆ(t) = (C(t, :)B) aˆ, ∀t = 2, · · · ,K. (18)
Now we have estimated the unseen GELs for t ≥ 2,
which allows us to predict drug response values for the whole
duration of the treatment. We start from xˆ(1) and estimate the
drug response for t = 1 as
yˆ(1) = f(xˆ(1), y˜(1)) (19)
where y˜(1) = 0. When yˆ(1) is available, we set y˜(2) = yˆ(1).
With the GEL estimate xˆ(2) from (18), we can predict yˆ(2) =
f(xˆ(2), y˜(2)), and so forth for the other time points.
Remark 2: Note that here we substitute predicted drug
responses for the unseen drug responses. Clearly, when actual
drug responses for past time ticks are available, they should
be used. We only do the substitution here for a preliminary
assessment of how well a patient is likely to respond over
time, before the beginning of treatment – which is naturally a
more ambitious goal.
III. SIMULATIONS
In this section, we provide some numerical experiments
to showcase the effectiveness of REP for drug response
prediction from time-course gene expression data. We apply
a number of drug response prediction methods including two
linear models (EN-LR [7] and SVM), one nonlinear model (K-
nearest neighbor (KNN) [23]), and a probabilistic graphical
model (discriminative loop hidden Markov model (dl-HMM)
[10]) to real-world time-course data. We did not include SVM
with nonlinear kernels (e.g. Gaussian), since its performance
was inferior compared to the linear kernel. Note that EN-LR
5and dl-HMM were specifically designed for prediction of drug
response values based on time-course gene expression data,
while SVM and KNN are widely used classification methods.
A. Dataset
The dataset used is the interferon (IFN)-β time-course
dataset which is available in the supplementary of [9]. The
dataset is collected from 53 Multiple Sclerosis (MS) pa-
tients who received IFN-β treatment for two years. The gene
expression data (microarray) was obtained from peripheral
blood mononuclear cells of the patients, which contained
the expression levels of 76 pre-selected genes over 7 stages
(i.e., time-points) of the treatment. However, there are missing
values in this dataset, where most missing values were caused
by the absence of patients at some stages. Among the patients,
only 27 patients have records for all stages, while the other 26
patients missed at least one stage, which resulted in the entire
GELs as well as the drug response at that stage being missed.
For ease of comparison, we only employ the 27 full records in
our experiments, where the final GEL data is with dimension
27× 7× 76 and the response data is with dimension 27× 7.
B. Evaluation metric
We use prediction accuracy (ACC) and area under receiver
operating characteristic (ROC) curve (AUC) to evaluate the
performance of REP, where ACC is defined as:
ACC =
TP + TN
TP + FP + FN + TN
and ROC curve is created by plotting true positive rate (TPR)
versus false positive rate (FPR), defined as
TPR =
TP
TP + FN
FPR =
FP
FP + TN
.
In the equations above, TP, FP, FN and TN stand for the num-
ber of true positives, false positives, false negatives and true
negatives, respectively. The ACC is calculated using 27-fold
cross validation, where in each fold, we select one patient’s
record as a testing set that contains a 7×76 GEL matrix and a
response vector with length 7, while the remaining 26 records
are assigned to the training set.
The hyper-parameters of EN-LR, SVM and KNN are tuned
through 5-fold cross validation, while those of REP are tuned
slightly differently: we first split the training data into a
training set and a validation set consisting of 25 and 1 records,
respectively, and then determine the final parameters as those
that achieve the highest prediction accuracy in the validation
set. It should be noted that the parameters of REP are tuned
once but not in a CV way, meaning that REP is tuned not
as accurately as the others. For REP, its hyper-parameters
include the rank F , and ρ in (10), which are selected from
F ∈ {2, 3, 4, 5} and λ ∈ {0.01, 0.1, 1, 10}. The SVM method
solves the following problem:
min
u,b
1
IK
I∑
i=1
K∑
t=1
max
(
0, 1− yi,t(uT zi,t + b)
)
+
λ
2
‖u‖22
(20)
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Fig. 2. Prediction accuracy comparison on raw data, where the percentage
of missing values is 0.23%.
where its parameter λ is tuned from {0.01, 0.1, 1, 10}; for EN-
LR, we set α = 0.5 which is a hyper-parameter balancing the
ridge and LASSO regularizations; for KNN, the number of
neighbors is selected from {3, 5, 8, 10}. After that, we apply
the trained classifier to the testing data to calculate ACC. We
implemented REP, EN-LR, SVM and KNN in Python 3.7.
Since the authors of dl-HMM have published their MATLAB
codes (http://www.cs.cmu.edu/∼thlin/tram/), we implemented
these two methods in MATLAB. For both HMM methods, we
choose the number of hidden states as 4 which is as suggested
in [10].
C. Results
TABLE I
ACC & AUC VERSUS PERCENTAGE OF MISSING VALUES
Metrics % miss REP EN-LR SVM KNN dl-HMM
ACC
5 94.8 90.5 88.4 70.4 65.1
10 92.6 88.4 88.7 69.3 59.6
15 89.4 85.2 81.6 64.3 59.6
20 88.5 84.7 81.5 66.8 55.6
AUC
5 96.9 93.0 91.2 50.2 53.9
10 96.8 90.1 88.6 49.4 54.7
15 95.4 87.4 84.3 51.9 54.7
20 93.2 88.1 87.1 52.3 56.4
Fig. 2 shows the prediction accuracy of the five algorithms.
In this example, the missing values is only 0.23%. For all the
methods, the missing GELs were completed using nonnegative
tensor completion in Section II-A. It can be seen that REP
achieves a higher prediction accuracy compared to other
methods and its performance is followed by the EN-LR and
SVM algorithms. The KNN and dl-HMM algorithms do not
perform well. We observed that dl-HMM was very sensitive
to the data, and it frequently produced not-a-number (NaN)
values. Particularly for patients with ID 1117161, 1215133 and
995640, the original codes of dl-HMM always produced NaN
of the three patients’ responses. This is the main reason why
dl-HMM had low prediction accuracy. We note that REP takes
a similar formulation as the SVM. However, REP is 6.2% more
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Fig. 4. Prediction accuracy of REP with estimated GEL.
accurate than SVM, which implies that the recursive structure
in REP is helpful in improving the prediction accuracy. In Fig.
3, the ROC curves are plotted, which shows that the proposed
method has the highest AUC value.
Next, we sought to determine the effect of missing values
on the performance of these methods. For this purpose, we
randomly sampled the GEL data and hid the selected entries.
As the percentage of missing values increases, we can see in
Table I that all methods suffer performance loss, but REP’s
ACC and AUC remain the highest in all cases. We highlight
that when the percentage of missing values is smaller than
15%, REP has ACC close to 90% and AUC greater than
95%. EN-LR outperforms the classical SVM method in many
cases. When the percentage of missing values increases, the
performance of EN-LR and SVM drops significantly, while
that of REP still remains at a high level. For example, when
percentage of missing increases to 15%, the AUC of EN-LR
drops to 87.4%, but ours is 95.4%, which indicates that REP
is more robust against missing values.
The above examples were conducted under the full knowl-
edge of GELs for each time point. However, we are more
interested in predicting the drug response in the beginning
of a treatment, meaning that we only have a few GELs at the
first time point while all the subsequent GELs are unavailable.
Specifically, we can first learn factors {B,C} using nonnega-
tive tensor completion, then follow the procedures in Section
II-C1 to predict the GELs, and finally, use the estimated GELs
for drug response prediction. To show the effectiveness of REP,
we only used the GELs of new patients at the first time point,
i.e., t = 1, while hiding the GELs for other time points through
t = 2 to 7. We studied the performance of REP where only
GELs for the first time-points were available. Fig. 4 shows the
prediction accuracy of REP by using estimated GELs, where
the percentage of missing stands for the missing values in the
training set. We see that REP with estimated GELs achieves
about 85% accuracy. Although this performance is not as good
as REP with the ground truth GELs (see Fig. 2), we must
emphasize that such performance is obtained by only knowing
the GELs from the first stage of the treatment, which is more
meaningful in practice.
IV. CONCLUSION
We studied the problem of drug response prediction for
time-course gene expression data and presented a compu-
tational algorithm (REP) that: (i) has a recursive structure
that integrates past drug response records for subsequent
predictions, (ii) offers higher prediction accuracy than several
classical algorithms such as SVM and LR, (iii) exploits the
tensor structure of the data for missing GEL completion
and unseen GEL prediction, (iv) can predict drug response
of different stages of a treatment from some initial GEL
measurements. The achieved performance improvement for
real data application suggests that our method serves as a better
predictor of drug response using the time-course data.
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